323 related articles for article (PubMed ID: 27163403)
1. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Choi JY; Ramasamy T; Kim SY; Kim J; Ku SK; Youn YS; Kim JR; Jeong JH; Choi HG; Yong CS; Kim JO
Acta Biomater; 2016 Jul; 39():94-105. PubMed ID: 27163403
[TBL] [Abstract][Full Text] [Related]
2. PEGylated polyaminoacid-capped mesoporous silica nanoparticles for mitochondria-targeted delivery of celastrol in solid tumors.
Choi JY; Gupta B; Ramasamy T; Jeong JH; Jin SG; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2018 May; 165():56-66. PubMed ID: 29453086
[TBL] [Abstract][Full Text] [Related]
3. Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth.
Choi JY; Ramasamy T; Tran TH; Ku SK; Shin BS; Choi HG; Yong CS; Kim JO
J Mater Chem B; 2015 Jan; 3(3):408-416. PubMed ID: 32262043
[TBL] [Abstract][Full Text] [Related]
4. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles.
Kang MS; Singh RK; Kim TH; Kim JH; Patel KD; Kim HW
Acta Biomater; 2017 Jun; 55():466-480. PubMed ID: 28373086
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
6. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
7. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells.
Niemelä E; Desai D; Nkizinkiko Y; Eriksson JE; Rosenholm JM
Eur J Pharm Biopharm; 2015 Oct; 96():11-21. PubMed ID: 26184689
[TBL] [Abstract][Full Text] [Related]
8. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
10. Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo.
Babaei M; Abnous K; Taghdisi SM; Taghavi S; Sh Saljooghi A; Ramezani M; Alibolandi M
Eur J Pharm Biopharm; 2020 Nov; 156():84-96. PubMed ID: 32882423
[TBL] [Abstract][Full Text] [Related]
11. Zwitterionic mesoporous nanoparticles with a bioresponsive gatekeeper for cancer therapy.
Khatoon S; Han HS; Lee M; Lee H; Jung DW; Thambi T; Ikram M; Kang YM; Yi GR; Park JH
Acta Biomater; 2016 Aug; 40():282-292. PubMed ID: 27063494
[TBL] [Abstract][Full Text] [Related]
12. Cancer cell membrane-cloaked mesoporous silica nanoparticles with a pH-sensitive gatekeeper for cancer treatment.
Liu CM; Chen GB; Chen HH; Zhang JB; Li HZ; Sheng MX; Weng WB; Guo SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():477-486. PubMed ID: 30572156
[TBL] [Abstract][Full Text] [Related]
13. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
[TBL] [Abstract][Full Text] [Related]
14. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
Hou L; Shan X; Hao L; Feng Q; Zhang Z
Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
[TBL] [Abstract][Full Text] [Related]
15. Anti-miRNA21 and resveratrol-loaded polysaccharide-based mesoporous silica nanoparticle for synergistic activity in gastric carcinoma.
Hu Y; Wang Z; Qiu Y; Liu Y; Ding M; Zhang Y
J Drug Target; 2019 Dec; 27(10):1135-1143. PubMed ID: 31017473
[TBL] [Abstract][Full Text] [Related]
16. Lipid Bilayer-Gated Mesoporous Silica Nanocarriers for Tumor-Targeted Delivery of Zoledronic Acid in Vivo.
Desai D; Zhang J; Sandholm J; Lehtimäki J; Grönroos T; Tuomela J; Rosenholm JM
Mol Pharm; 2017 Sep; 14(9):3218-3227. PubMed ID: 28737925
[TBL] [Abstract][Full Text] [Related]
17. Aerosol technique-based carbon-encapsulated hollow mesoporous silica nanoparticles for synergistic chemo-photothermal therapy.
Gautam M; Thapa RK; Poudel BK; Gupta B; Ruttala HB; Nguyen HT; Soe ZC; Ou W; Poudel K; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2019 Apr; 88():448-461. PubMed ID: 30818051
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models.
Badr G; Al-Sadoon MK; Rabah DM
Free Radic Biol Med; 2013 Dec; 65():175-189. PubMed ID: 23811005
[TBL] [Abstract][Full Text] [Related]
19. PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden.
Gao J; Fan K; Jin Y; Zhao L; Wang Q; Tang Y; Xu H; Liu Z; Wang S; Lin J; Lin D
Eur J Pharm Sci; 2019 Dec; 140():105070. PubMed ID: 31518679
[TBL] [Abstract][Full Text] [Related]
20. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Song Y; Zhou B; Du X; Wang Y; Zhang J; Ai Y; Xia Z; Zhao G
Biomed Pharmacother; 2020 May; 125():109561. PubMed ID: 32106385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
